Novel lactobacillus brevis ne428 strain and use thereof

Abstract

The present invention relates to a novel Lactobacillus brevis NE428 strain and uses thereof. More specifically, the present invention relates to a Lactobacillus brevis NE428 strain (accession number: KCTC15727BP), a pharmaceutical composition comprising the strain as an active ingredient for preventing or treating Graves' disease, and a health functional food for preventing or alleviating Graves' disease. The novel Lactobacillus brevis NE428 strain according to the present invention has an effect of preventing, alleviating, and treating Graves' disease by, for example, reducing the concentration of thyroid hormones elevated in the blood by Graves' disease and decreasing thyroid size, and thus can be advantageously used in the preparation of a novel therapeutic agent and health functional food for Graves' disease.

Description

Novel Lactobacillus brevis NE428 strain and its use

[0001] The present invention relates to a novel Lactobacillus brevis NE428 strain and its use.

[0002] Graves' disease (GD) is an autoimmune disease affecting the thyroid gland. The patient's own immune cells produce antibodies that bind to thyroid cells. These antibodies stimulate the thyroid gland, causing it to produce excessive amounts of thyroid-stimulating hormone. These antibodies also react with the tissue behind the eye, causing eye symptoms such as bulging eyes.

[0003] Meanwhile, the exact cause of Graves' disease is unknown, but it is predicted that a combination of genetic and environmental factors may play a role.

[0004] Treatment options for Graves' disease include antithyroid drugs, which reduce thyroid hormone production, radioactive iodine therapy, and thyroidectomy (surgical removal of the thyroid gland). Because immediate surgery is risky for patients with hyperthyroidism, antithyroid drugs are administered before thyroidectomy to induce hypothyroidism before surgery.

[0005] Antithyroid drug treatment requires six months to two years to be effective, and hyperthyroidism can recur when the medication is discontinued. The risk of relapse is approximately 40-50%, and lifelong antithyroid drug treatment can lead to side effects such as agranulocytosis and liver disease. Furthermore, antithyroid drugs can cause potentially fatal low white blood cell counts. Radioactive iodine therapy is the most common treatment in the United States, but it requires daily thyroid hormone replacement, is administered slowly (over months to years) to destroy the thyroid gland, and may not be effective in all patients.

[0006] Therefore, there is a need to develop a new treatment for Graves' disease that has excellent therapeutic effects without causing side effects in the body.

[0007] Accordingly, the inventors of the present invention completed the present invention by confirming that the novel Lactobacillus brevis NE428 strain isolated from kimchi has excellent preventive, improvement and treatment effects on Graves' disease while conducting research to discover a new treatment targeting lactic acid bacteria that is safe for the body and can solve the problems of the existing Graves' disease treatment methods.

[0008] Therefore, the purpose of the present invention is to provide a novel Lactobacillus brevis NE428 strain (Accession No.: KCTC15727BP).

[0009] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating Graves' disease, comprising Lactobacillus brevis NE428 strain (Accession No.: KCTC15727BP) as an active ingredient.

[0010] Another object of the present invention is to provide a health functional food for preventing or improving Graves' disease, comprising Lactobacillus brevis NE428 strain (Accession No.: KCTC15727BP) as an active ingredient.

[0011] In order to achieve the above-described purpose of the present invention, the present invention provides Lactobacillus brevis NE428 strain (Accession No.: KCTC15727BP).

[0012] In one embodiment of the present invention, the strain may be isolated and identified from kimchi.

[0013] In addition, the present invention provides a pharmaceutical composition for preventing or treating Graves' disease, comprising Lactobacillus brevis NE428 strain (Accession No.: KCTC15727BP) as an active ingredient.

[0014] In one embodiment of the present invention, the strain may be selected from among a cell of the strain, a fragment of the cell, a culture of the strain, a culture solution from which the cell is removed from the culture of the strain, a cell extract of the strain, an extract of the culture of the strain, or an extract of the culture solution from which the cell is removed from the culture of the strain.

[0015] In one embodiment of the present invention, the strain may be isolated and identified from kimchi.

[0016] In one embodiment of the present invention, the composition may have an effect of reducing the concentration of thyroid hormones in the blood increased by Graves' disease and reducing the size of the thyroid gland.

[0017] In addition, the present invention provides a health functional food for preventing or improving Graves' disease, comprising Lactobacillus brevis NE428 strain (Accession No.: KCTC15727BP) as an active ingredient.

[0018] In one embodiment of the present invention, the strain may be selected from among a cell of the strain, a fragment of the cell, a culture of the strain, a culture solution from which the cell is removed from the culture of the strain, a cell extract of the strain, an extract of the culture of the strain, or an extract of the culture solution from which the cell is removed from the culture of the strain.

[0019] In one embodiment of the present invention, the strain may be isolated and identified from kimchi.

[0020] In one embodiment of the present invention, the composition may have an effect of reducing the concentration of thyroid hormones in the blood increased by Graves' disease and reducing the size of the thyroid gland.

[0021] The novel Lactobacillus brevis NE428 strain according to the present invention has the effect of preventing, improving and treating Graves' disease by reducing the concentration of thyroid hormones increased in the blood due to Graves' disease and reducing the size of the thyroid gland, and thus can be usefully used in the manufacture of new therapeutic agents and health functional foods for Graves' disease.

[0022] Figure 1 shows an experimental schedule for establishing a Graves' disease mouse model and administering lactic acid bacteria isolated from kimchi in one embodiment of the present invention.

[0023] Figure 2 shows the results of confirming the efficacy of the Lactobacillus brevis NE428 strain selected in the present invention among lactic acid bacteria isolated from kimchi in reducing the increase in T4 in the blood. Blood was collected from a control group (PBS treatment group, EGFP expression-induced group), a group of Graves' disease mice administered an adenovirus (Ad-TSHR) that induces TSHR expression (Ad-TSHR), and a group of mice administered Ad-TSHR and the new Lactobacillus brevis NE428 strain of the present invention together, and the results of analyzing the level of T4 in the blood are shown.

[0024] Figure 3 shows the results of analyzing the level of T4 in the blood after 2 weeks (upper figure) and 3 weeks (lower figure) from normal mice, EGFP expression-induced control group, Graves' disease mice administered adenovirus (Ad-TSHR) that induces TSHR expression, a group administered Ad-TSHR together with PTU, a known Graves' disease treatment agent, and a group administered Ad-TSHR together with the new strain of Lactobacillus brevis NE428 of the present invention.

[0025] Figure 4 shows photographs of thyroid tissues isolated from normal mice treated only with PBS, a control group for inducing EGFP expression, a group of Graves' disease mice administered an adenovirus (Ad-TSHR) for inducing TSHR expression (Ad-TSHR), and a group of mice administered Ad-TSHR and the new strain of Lactobacillus brevis NE428 of the present invention together, and observing the color and size.

[0026] The present invention is characterized by the discovery that a novel strain of Lactobacillus brevis NE428 can be used as a new therapeutic agent for preventing or treating Graves' disease (GD).

[0027] The present inventors, while conducting research to develop a microbial treatment agent rather than the synthetic compounds that have been used in the past as a new treatment agent for Graves' disease, isolated a number of lactic acid bacteria from kimchi, and selected the lactic acid bacteria that can most effectively suppress the concentration of thyroid hormone (thyroxine (T4)) in the blood that appears when Graves' disease develops among the isolated lactic acid bacteria, and as a result, identified a novel, previously unknown Lactobacillus brevis strain, named it 'Lactobacillus brevis NE428', and deposited it with the Biological Resource Center of the Korea Research Institute of Bioscience and Biotechnology on December 8, 2023, and was assigned the accession number KCTC15727BP.

[0028] Therefore, the present invention can provide a novel Lactobacillus brevis NE428 strain (accession number: KCTC15727BP).

[0029] In addition, the present invention can provide a pharmaceutical composition for preventing or treating Graves' disease, comprising Lactobacillus brevis NE428 strain (Accession No.: KCTC15727BP) as an active ingredient.

[0030] In the present invention, the strain that can be included as an effective ingredient in the composition is not limited thereto, but may include all of the strain cells, the lysate of the strain cells, the culture of the strain, the culture solution from which the strain cells have been removed from the culture of the strain, the strain cell extract, the extract of the strain culture, or the extract of the culture solution from which the strain cells have been removed from the culture of the strain.

[0031] In addition, the new strain of Lactobacillus brevis NE428 (accession number: KCTC15727BP) of the present invention has the characteristic of being able to prevent and treat Graves' disease.

[0032] In one embodiment of the present invention, a group of mice were administered with an adenovirus having a Thyroid Stimulating Hormone Receptor (TSHR) gene introduced therein to induce Graves' disease, together with the Lactobacillus brevis NE428 strain of the present invention, and a group of mice in which Graves' disease was induced by administering only the adenovirus having the TSHR gene introduced therein (Ad-TSHR) and a control group (PBS treatment group, group administered with an adenovirus having an EGFR gene introduced therein instead of TSHR). The thyroid glands were then extracted from each group, and the size and color of the thyroid glands were analyzed.

[0033] As a result, in the group of mice in which Graves' disease was induced by TSHR overexpression, the size of the thyroid gland was found to be significantly increased compared to the control group, and the color also changed to dark brown.

[0034] On the other hand, the group treated with the Lactobacillus brevis NE428 strain of the present invention was found to have a size and color of the thyroid gland that were almost similar to those of the control group.

[0035] Through these results, the inventors of the present invention were able to determine that the novel Lactobacillus brevis NE428 strain of the present invention has the effect of preventing and treating Graves' disease.

[0036] In another embodiment of the present invention, after Graves' disease was induced in mice, the new strain of Lactobacillus brevis NE428 of the present invention was orally administered to the mice. As a result, the group treated with the new strain of the present invention showed a significant decrease in the concentration of thyroid hormone (T4) in the blood compared to the group not treated with the new strain, and this effect was shown to be at a similar level to the group treated with PTU, which is known as a conventional Graves' disease treatment agent.

[0037] Through these results, the inventors were able to reconfirm that the Lactobacillus brevis NE428 strain of the present invention is effective in preventing and treating Graves' disease.

[0038] The pharmaceutical composition according to the present invention can be formulated and used in the form of oral preparations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, and sterile injection solutions, respectively, according to conventional methods, and may include appropriate carriers, excipients, or diluents conventionally used in the manufacture of pharmaceutical compositions for formulation.

[0039] The carrier or excipient or diluent may include various compounds or mixtures including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

[0040] When formulating, it can be manufactured using diluents or excipients such as fillers, weighting agents, binders, wetting agents, disintegrants, and surfactants that are commonly used.

[0041] Solid formulations for oral administration can be prepared by mixing the Lactobacillus brevis NE428 strain of the present invention with at least one excipient, such as starch, calcium bonate, sucrose or lactose, or gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc can also be used.

[0042] Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups, and in addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients such as wetting agents, sweeteners, fragrances, and preservatives.

[0043] Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solutions and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases include witepsol, macrogol, Tween 61, cocoa butter, laurin, and glycerol gelatin.

[0044] The preferred dosage of the pharmaceutical composition according to the present invention varies depending on the patient's condition, body weight, severity of the disease, drug form, route of administration, and duration of administration, but can be appropriately selected by those skilled in the art. However, for desirable effects, the dosage may be 0.0001 to 2,000 mg / kg per day, preferably 0.001 to 2,000 mg / kg. Administration may be once a day or divided into several doses. However, the scope of the present invention is not limited by the above dosage.

[0045] The pharmaceutical composition according to the present invention can be administered to mammals such as rats, mice, livestock, and humans via various routes. All modes of administration can be administered, for example, orally, rectally, or by intravenous, intramuscular, or subcutaneous injection.

[0046] In addition, the present invention can provide a health functional food for preventing or improving Graves' disease, which contains Lactobacillus brevis NE428 strain (Accession No.: KCTC15727BP) as an active ingredient.

[0047] The strain is as described above, and the dose of the new strain of the present invention is 1Х10 6 CFU / mL to 1Х10 10 It can be CFU / mL, 1Х10 8 CFU / mL to 1Х10 10 It is desirable to have CFU / mL, but is not limited to this.

[0048] In the health functional food composition according to the present invention, when the Lactobacillus brevis NE428 strain (Accession No.: KCTC15727BP) is used as an additive to a health functional food, it may be added as is or used together with other foods or food ingredients, and may be used appropriately according to a conventional method. The mixing amount of the active ingredients may be appropriately determined depending on each purpose of use, such as prevention, health, or treatment.

[0049] The formulation of health functional foods can be in the form of powders, granules, pills, tablets, capsules, or any other form of general food or beverage.

[0050] There is no particular limitation on the types of the above foods, and examples of foods to which the above substances can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and all foods in the conventional sense can be included.

[0051] In general, when manufacturing food or beverages, the new strain of the present invention may be added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, per 100 parts by weight of the raw material. However, in the case of long-term intake for health and hygiene purposes or health control purposes, the amount may be below the above range.

[0052] Among the health functional foods according to the present invention, the beverage may contain various flavoring agents or natural carbohydrates as additional ingredients, just like conventional beverages. The natural carbohydrates mentioned above may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a sweetener, a natural sweetener such as thaumatin or stevia extract, or a synthetic sweetener such as saccharin or aspartame may be used. The proportion of the natural carbohydrate may be about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g, per 100 mL of the beverage according to the present invention.

[0053] In addition to the above, the health functional food composition according to the present invention may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, and carbonating agents used in carbonated beverages. In addition, the health functional food composition according to the present invention may contain fruit pulp for the production of natural fruit juice, fruit juice drinks, and vegetable drinks. These ingredients may be used independently or in mixtures. The ratio of these additives is not limited, but is generally selected in the range of 0.01 to 0.1 parts by weight relative to 100 parts by weight of the health functional food composition according to the present invention.

[0054] In addition, since the Lactobacillus brevis NE428 strain according to the present invention was isolated from kimchi, it can be used to manufacture a fermented food by adding it to a fermentation starter or a starter composition for fermented food.

[0055] The above fermented foods may be diverse, including yogurt, kimchi, and cheese, and the above fermented foods may also have a preventive or improvement effect on Graves' disease.

[0056] Hereinafter, the present invention will be described in more detail through examples. These examples are intended to more specifically illustrate the present invention, and the scope of the present invention is not limited to these examples.

[0057]

[0058] <Example 1>

[0059] Isolation and identification of a novel Lactobacillus brevis NE428 strain from kimchi.

[0060] To isolate and identify microorganisms with Graves' disease-treating properties from kimchi, the inventors conducted the following experiments. Commercially available kimchi was suspended in sterile water, spread on MRS agar plates, and cultured. Single colonies were collected. Each colony was cultured, and the 16s rRNA sequences of each strain were analyzed.

[0061] A total of 32 colonies were isolated from various types of kimchi, and analysis of the 16s rRNA sequence revealed that they were lactic acid bacteria such as Lactobacillus brevis, Lactobacillus sakei, Lactobacillus curbatus, Leuconostoc mesenteroides, and Leuconostoc lactis.

[0062]

[0063] <Example 2>

[0064] Confirmation of the therapeutic efficacy of the novel strain Lactobacillus brevis NE428 according to the present invention against Graves' disease.

[0065] To select lactic acid bacteria with the efficacy of treating Graves' disease among lactic acid bacteria isolated from kimchi, the following experiments were conducted using an animal model of Graves' disease.

[0066] After administering the kimchi-derived lactic acid bacteria isolated in the present invention and an adenovirus having a coding base sequence of a peptide including the 1st to 289th amino acids of the TSHR (thyroid stimulating hormone receptor) protein to 6-week-old Balb / c female mice, improvement in Graves' disease following administration of the lactic acid bacteria was confirmed by measuring the concentration of blood thyroid hormone T4. Here, the amino acid sequence of the TSHR protein is shown in SEQ ID NO: 2.

[0067] In addition, administration of adenovirus containing the base sequence encoding the above TSHR protein is 10 10 The particles were administered three times for three weeks each, and lactic acid bacteria were administered at 10 9 / kg was administered daily for 9 weeks (Fig. 1). The experiment was conducted in a total of 9 groups (PBS, EGFP, Ad-TSHR, and lactic acid bacteria treatment), including a control group, with 5 mice per group.

[0068] Virus Lactic Acid Bacteria Injection Location Thigh Oral BufferPBSPBSConcentration10 10 10 9 / kgVolume40ul50ulTermEvery 3 weeks, 3 times, 9 weeks, daily

[0069]

[0070] The analysis results showed that, compared to the control group (PBS, EGFP treatment group) that did not induce Graves' disease, the blood T4 (thyroxine) concentration in the blood of mice that were induced with Graves' disease for 9 weeks with Ad-TSHR increased by approximately 3 times compared to before induction.

[0071] These results indicate that a Graves' disease mouse model was well established through infection with an adenovirus into which the TSHR base sequence according to the present invention was introduced.

[0072] In addition, as a result of analyzing the increase in blood T4 in a group of mice that were administered lactic acid bacteria isolated from kimchi at the same time as inducing a Graves' disease mouse model with Ad-TSHR, the group treated with lactic acid bacteria showed a reduced increase in blood T4 compared to the control group and the group administered Ad-TSHR alone. After selecting a strain that showed a significantly lower increase in blood T4 compared to other lactic acid bacteria, the 16s rRNA base sequence of the strain was analyzed.

[0073] As a result, the selected strain was confirmed to have 99% homology with the Lactobacillus brevis strain and to be a novel strain not previously known. The 16s rRNA sequence of the novel Lactobacillus brevis NE428 strain identified in the present invention is shown in SEQ ID NO: 1.

[0074] The results of confirming a decrease in the increase in blood T4 following treatment with the Lactobacillus brevis strain selected in the above experiment are shown in Fig. 2. This shows the possibility that Lactobacillus brevis can prevent Graves' disease.

[0075] Accordingly, the inventors of the present invention named the strain 'Lactobacillus brevis NE428' and deposited it with the Biological Resource Center of the Korea Research Institute of Bioscience and Biotechnology on December 8, 2023, and were assigned the deposit number KCTC15727BP.

[0076]

[0077] <Example 3>

[0078] Confirmation of the therapeutic efficacy of the novel strain Lactobacillus brevis NE428 according to the present invention against Graves' disease.

[0079] The present inventors performed the following experiment to confirm whether the novel strain of Lactobacillus brevis NE428 identified in Example 1 had a preventive effect on Graves' disease in Example 2. To this end, Graves' disease was first induced in a mouse animal model for 9 weeks, and then the Lactobacillus brevis NE428 strain of the present invention was treated to confirm the preventive or therapeutic effect of the novel strain of the present invention on Graves' disease. At this time, the Lactobacillus brevis NE428 strain of the present invention was 10 9 / kg of the bacteria were administered orally to experimental mice daily for 3 weeks, and each experimental group consisted of 10 mice.

[0080] Blood samples were then collected from mice in each experimental group, and the concentration of T4 in the blood was determined. Blood T4 concentrations were measured by collecting blood samples 2 and 3 weeks after ingestion of the Lactobacillus brevis NE428 strain.

[0081]

[0082] As a result, as shown in Fig. 3, when the concentration of T4 in the blood was analyzed 2 weeks after ingestion of the Lactobacillus brevis NE428 strain, the mice treated with PBS, the control group, and those overexpressing EGFP were found to maintain a low level of T4 concentration, but the group overexpressing Ad-TSHR showed an increase in the T4 concentration of about 5 times compared to the control group treated with PBS. On the other hand, the group treated with PTU, one of the Graves' disease treatment agents, showed a decrease in the T4 concentration of about 30% compared to the group overexpressing Ad-TSHR, and it was also confirmed that the group treated with the Lactobacillus brevis NE428 strain of the present invention showed a decrease in the T4 concentration of about 30% compared to the group overexpressing Ad-TSHR. The concentration of T4 in the blood 3 weeks after ingestion of the strain of the present invention was similar to that 2 weeks after ingestion of the strain of the present invention.

[0083]

[0084] Furthermore, the inventors extracted the thyroid glands from each of the experimental groups of mice and analyzed the changes in size.

[0085] As a result, as shown in Figure 4, there was no significant change or difference in the color or size of the thyroid gland between the PBS-treated control group and the EGFP-expressing group. On the other hand, in the group overexpressing Ad-TSHR, the thyroid gland was confirmed to be darker in color and larger in size than the control group (PBS-treated group). These results correspond to one of the characteristics of Graves' disease.

[0086] Meanwhile, when Ad-TSHR was overexpressed and PTU (propylthio uracil), a currently known therapeutic agent, was treated, it was confirmed that the color of the thyroid gland became lighter, and in particular, in the case of the group treated with Lactobacillus brevis NE428 of the present invention, it was confirmed that the color and size of the thyroid gland were almost similar to those of the control group (PBS treatment group) and the PTU treatment group.

[0087]

[0088] Through these results, the inventors of the present invention were able to find that the novel Lactobacillus brevis NE428 strain identified in the present invention can prevent, improve, and treat the symptoms of Graves' disease.

[0089] Through the above results, the inventors of the present invention were able to find that the new strain of Lactobacillus brevis NE428 isolated and identified from kimchi can be usefully used in medicines and health functional foods that can prevent, improve, or treat Graves' disease.

[0090]

[0091] The present invention has been described above, focusing on preferred embodiments thereof. Those skilled in the art will appreciate that the present invention can be implemented in modified forms without departing from its essential characteristics. Therefore, the disclosed embodiments should be considered illustrative rather than limiting. The scope of the present invention is set forth in the claims, not the foregoing description, and all differences within the scope equivalent thereto should be construed as being encompassed by the present invention.

[0092]

[0093] Name of depositor: Korea Research Institute of Bioscience and Biotechnology, Biological Resource Center (KCTC)

[0094] Accession number: KCTC15727BP

[0095] Date of acceptance: 20231208

[0096] The strain deposit certificate of the Lactobacillus brevis NE428 strain of the present invention is as follows.

[0097] [Correction pursuant to Rule 91 dated February 27, 2025]

Claims

1. Lactobacillus brevis NE428 strain (Accession number: KCTC15727BP).

2. In paragraph 1, The above strain is Lactobacillus brevis NE428, characterized in that it is isolated and identified from kimchi.

3. A pharmaceutical composition for preventing or treating Graves' disease, comprising Lactobacillus brevis NE428 strain (Accession No.: KCTC15727BP) as an active ingredient.

4. In paragraph 3, A pharmaceutical composition for preventing or treating Graves' disease, characterized in that the strain is selected from among cells of the strain, a fragment of cells, a culture of the strain, a culture solution from which cells have been removed from a culture of the strain, an extract of cells of the strain, an extract of a culture of the strain, or an extract of a culture solution from which cells have been removed from a culture of the strain.

5. In paragraph 3, A pharmaceutical composition for preventing or treating Graves' disease, characterized in that the strain is isolated and identified from kimchi.

6. In paragraph 3, A pharmaceutical composition for preventing or treating Graves' disease, characterized in that the composition has the effect of reducing the concentration of thyroid hormone increased in the blood due to Graves' disease and reducing the size of the thyroid gland.

7. A health functional food for preventing or improving Graves' disease, containing Lactobacillus brevis NE428 strain (Accession Number: KCTC15727BP) as an active ingredient.

8. In paragraph 7, A health functional food for preventing or improving Graves' disease, characterized in that the strain is selected from among cells of the strain, a fragment of cells, a culture of the strain, a culture solution from which cells have been removed from a culture of the strain, an extract of cells of the strain, an extract of a culture of the strain, or an extract of a culture solution from which cells have been removed from a culture of the strain.

9. In paragraph 7, A health functional food for preventing or improving Graves' disease, characterized in that the above strain is isolated and identified from kimchi.

10. In paragraph 7, The composition is a health functional food for preventing or improving Graves' disease, characterized in that it has the effect of reducing the concentration of thyroid hormone increased in the blood due to Graves' disease and reducing the size of the thyroid gland.

Images